Clinical Edge Journal Scan

Early application of a standardized skin care product does not prevent atopic dermatitis in predisposed infants


 

Key clinical point: Regular application of a standardized skin care regimen during the first year of life did not prevent the development of atopic dermatitis (AD) in predisposed infants.

Major finding: In the first year of life, the overall cumulative incidence rate of AD was similar with regular standardized skin care and no predetermined skin care/skin care preferred by parents (odds ratio 1.0; P = .999).

Study details : Findings are from a prospective trial (ADAPI) including 150 infants who were at an enhanced risk of developing AD and were randomly assigned to receive a regular standardized skin care regimen or skin care as preferred by parents.

Disclosures: The study was sponsored by HiPP GmbH & Co Vertrieb KG, Germany. Two authors declared being employees of HiPP GmbH & Co Vertrieb KG. The other authors declared no conflicts of interest.

Source: Kottner J et al for the ADAPI Study Group. Effectiveness of a standardized skin care regimen to prevent atopic dermatitis in infants at risk for atopy: A randomized, pragmatic, parallel-group study. J Eur Acad Dermatol Venereol. 2022 (Oct 29). Doi: 10.1111/jdv.18698

Recommended Reading

Serum dupilumab levels do not predict clinical response
MDedge Dermatology
Atopic dermatitis: Dupilumab serum levels not associated with treatment response or adverse effects
MDedge Dermatology
Exposure to wildfire air pollution increases atopic dermatitis risk in older adults
MDedge Dermatology
Moderate-to-severe atopic dermatitis: No increased infection risk with long-term dupilumab use
MDedge Dermatology
Long-term efficacy of baricitinib in moderate-to-severe atopic dermatitis
MDedge Dermatology
Long-term efficacy of baricitinib in moderate-to-severe atopic dermatitis
MDedge Dermatology
Atopic dermatitis patients with good clinical response or conjunctivitis may opt for longer dupilumab dosing interval
MDedge Dermatology
Topical prebiotics and postbiotics effective and well tolerated in mild-to-moderate atopic dermatitis
MDedge Dermatology
Emollient use in the first year of life does not protect against atopic dermatitis in the long term
MDedge Dermatology
Topical POLG nanoemulsion improves dryness and itchiness in atopic dermatitis
MDedge Dermatology